An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.

FDA blocks new use for AstraZeneca's Ultomiris AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris ...